{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:41:15Z","timestamp":1793832075966,"version":"4.6.1"},"reference-count":22,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["EY027691"],"award-info":[{"award-number":["EY027691"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of VitreoRetinal Diseases"],"published-print":{"date-parts":[[2020,7]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To analyze a case series of retinal vasculitis reported to the American Society of Retina Specialists (ASRS) following Food and Drug Administration approval of brolucizumab for treatment of neovascular age-related macular degeneration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>The ASRS Research and Safety in Therapeutics Committee analyzed clinical and imaging characteristics from submitted reports of retinal vasculitis after brolucizumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Retinal vasculitis was reported in 26 eyes of 25 patients (22 [88%] female) after treatment with brolucizumab. Imaging studies were available for 24 of 26 eyes. Most cases (92%) were associated with intraocular inflammation, which presented at a mean of 25 days (range, 3-63 days) after the most recent brolucizumab injection. Mean visual acuity (VA) was 20\/52 (range, 20\/25-4\/200) before the adverse event, 20\/151 (range, 20\/25-hand motion) at presentation of the adverse event, and 20\/243 (range, 20\/30-light perception) at last follow-up. Twelve eyes (46%) had a greater than 3-line decrease in VA at final follow-up, and 12 eyes (46%) had a final VA of 20\/200 or worse. Analysis of retinal imaging identified vasculopathy that involved retinal arteries (91%), retinal veins (79%), and choroidal vessels (48%). Occlusive disease was apparent on imaging in 83% of eyes. Treatment approaches were varied.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Retinal vasculitis has been identified in a series of eyes following brolucizumab. Although a few eyes in this series were asymptomatic or minimally symptomatic, some eyes had significant vision loss. A careful examination for signs of active inflammation prior to brolucizumab injection is recommended. Once vasculopathy is suspected, angiographic imaging may help define the spectrum of involvement. Optimal treatment strategies remain unknown.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/2474126420930863","type":"journal-article","created":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T06:36:10Z","timestamp":1593585370000},"page":"269-279","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":172,"title":["Occlusive Retinal Vasculitis Following Intravitreal Brolucizumab"],"prefix":"10.1177","volume":"4","author":[{"given":"Andre J.","family":"Witkin","sequence":"first","affiliation":[{"name":"Tufts Medical Center, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Hahn","sequence":"additional","affiliation":[{"name":"NJ Retina, Teaneck, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy G.","family":"Murray","sequence":"additional","affiliation":[{"name":"Murray Ocular Oncology and Retina, Miami, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Fernando","family":"Arevalo","sequence":"additional","affiliation":[{"name":"Wilmer Eye Institute at Johns Hopkins Hospital, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3648-3772","authenticated-orcid":false,"given":"Kevin J.","family":"Blinder","sequence":"additional","affiliation":[{"name":"The Retina Institute, St Louis, MO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Netan","family":"Choudhry","sequence":"additional","affiliation":[{"name":"Vitreous Retina Macula Specialists of Toronto, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoff G.","family":"Emerson","sequence":"additional","affiliation":[{"name":"Retina Center of Minnesota, Minneapolis, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3334-5414","authenticated-orcid":false,"given":"Roger A.","family":"Goldberg","sequence":"additional","affiliation":[{"name":"Bay Area Retina Associates, Walnut Creek, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Kim","sequence":"additional","affiliation":[{"name":"Vanderbilt University Medical Center, Nashville, TN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Pearlman","sequence":"additional","affiliation":[{"name":"Retinal Consultants, Sacramento, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric W.","family":"Schneider","sequence":"additional","affiliation":[{"name":"Tennessee Retina, Nashville, TN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Homayoun","family":"Tabandeh","sequence":"additional","affiliation":[{"name":"Retina-Vitreous Associates Medical Group, Los Angeles, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert W.","family":"Wong","sequence":"additional","affiliation":[{"name":"Austin Retina Associates, Austin, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2020,7,1]]},"reference":[{"key":"bibr1-2474126420930863","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.04.017"},{"key":"bibr2-2474126420930863","first-page":"18","volume":"100680","author":"Haug SJ","year":"2020","journal-title":"Am J Ophthalmol Case Rep"},{"key":"bibr3-2474126420930863","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2020.100687"},{"key":"bibr4-2474126420930863","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/943409"},{"key":"bibr5-2474126420930863","doi-asserted-by":"publisher","DOI":"10.1097\/ICU.0b013e32835f8ec0"},{"key":"bibr6-2474126420930863","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2014.06.019"},{"key":"bibr7-2474126420930863","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2014.5650"},{"key":"bibr8-2474126420930863","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2019.04.006"},{"key":"bibr9-2474126420930863","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2008.138479"},{"key":"bibr10-2474126420930863","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e3181baf691"},{"key":"bibr11-2474126420930863","doi-asserted-by":"publisher","DOI":"10.3928\/23258160-20190503-05"},{"key":"bibr12-2474126420930863","unstructured":"US Food and Drug Administration. Center for Drug Evaluation and Research. Published September 25, 2019. Accessed June 11, 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/761125Orig1s000SumR.pdf"},{"key":"bibr13-2474126420930863","unstructured":"US Food and Drug Administration. Published October 2019. Accessed June 11, 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/761125s000lbl.pdf"},{"key":"bibr14-2474126420930863","unstructured":"US Food and Drug Administration. Center for Drug Evaluation and Research. Published April 15, 2017. Accessed June 11, 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/125156Orig1s114.pdf"},{"key":"bibr15-2474126420930863","unstructured":"US Food and Drug Administration. Center for Drug Evaluation and Research. Published March 30, 2012. Accessed June 11, 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/125418Orig1s000ClinPharmR.pdf"},{"key":"bibr16-2474126420930863","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-3768.2009.01535.x"},{"key":"bibr17-2474126420930863","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2415-13-60"},{"key":"bibr18-2474126420930863","doi-asserted-by":"publisher","DOI":"10.1111\/aos.14058"},{"key":"bibr19-2474126420930863","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.10-5842"},{"key":"bibr20-2474126420930863","doi-asserted-by":"publisher","DOI":"10.1177\/2474126418806832"},{"key":"bibr21-2474126420930863","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2016.11.042"},{"key":"bibr22-2474126420930863","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2018.01.030"}],"container-title":["Journal of VitreoRetinal Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2474126420930863","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/2474126420930863","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2474126420930863","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:26:05Z","timestamp":1790695565000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/2474126420930863"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["10.1177\/2474126420930863"],"URL":"https:\/\/doi.org\/10.1177\/2474126420930863","relation":{},"ISSN":["2474-1264","2474-1272"],"issn-type":[{"value":"2474-1264","type":"print"},{"value":"2474-1272","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7]]}}}